Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver Trial.
作者信息
Tapper Elliot B, Zhao Zhe, Henderson James
机构信息
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
出版信息
Hepatol Commun. 2024 Sep 18;8(10). doi: 10.1097/HC9.0000000000000530. eCollection 2024 Oct 1.
Abstract
摘要
相似文献
1
Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver Trial.他汀类药物预防肝硬化并发症：美国对StatLiver试验的效仿。
Hepatol Commun. 2024 Sep 18;8(10). doi: 10.1097/HC9.0000000000000530. eCollection 2024 Oct 1.
2
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.他汀类药物在慢性肝病和肝硬化患者中的应用：当前观点与前景
Curr Gastroenterol Rep. 2017 Sep;19(9):43. doi: 10.1007/s11894-017-0584-7.
3
Statins in Cirrhosis: The Magic Pill?肝硬化中的他汀类药物：神奇药丸？
Hepatology. 2016 Jun;63(6):2047-9. doi: 10.1002/hep.28616.
4
[The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients].[非选择性β受体阻滞剂、血管紧张素受体拮抗剂及他汀类药物在肝硬化患者中的应用]
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):923-928. doi: 10.3760/cma.j.issn.1007-3418.2019.12.004.
5
Pleiotropic effects of statins in the diseases of the liver.他汀类药物在肝脏疾病中的多效性作用。
World J Gastroenterol. 2016 Jul 21;22(27):6201-13. doi: 10.3748/wjg.v22.i27.6201.
6
How strong is the evidence to support statins repurposing for the treatment of cirrhosis?支持他汀类药物重新用于治疗肝硬化的证据有多充分？
Rev Esp Enferm Dig. 2023 Mar;115(3):107-109. doi: 10.17235/reed.2022.9281/2022.
7
Statins in Cirrhosis: Trial Data Are in but the Jury Is Still Out.肝硬化患者使用他汀类药物：试验数据已出，但仍无定论。
Dig Dis Sci. 2023 Aug;68(8):3216-3217. doi: 10.1007/s10620-023-07970-w. Epub 2023 May 22.
8
Statins for non-alcoholic fatty liver disease: a new indication?他汀类药物用于非酒精性脂肪性肝病：一种新的适应症？
Aliment Pharmacol Ther. 2006 Aug 15;24(4):698-9. doi: 10.1111/j.1365-2036.2006.03021.x.
9
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.SACRED：辛伐他汀对高危代偿性肝硬化患者肝失代偿和死亡的影响：他汀类药物与肝硬化：减少失代偿事件。
Contemp Clin Trials. 2021 May;104:106367. doi: 10.1016/j.cct.2021.106367. Epub 2021 Mar 24.
10
Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy.在肝硬化患者的标准治疗中添加他汀类药物：安全性和疗效。
World J Gastroenterol. 2021 Jul 28;27(28):4639-4652. doi: 10.3748/wjg.v27.i28.4639.
引用本文的文献
1
Statins in Metabolic Dysfunction-Associated Liver Disease: Hope, Hurdles, and Biostatistical Hazards.他汀类药物在代谢功能障碍相关肝病中的应用：希望、障碍及生物统计学风险
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102504. doi: 10.1016/j.jceh.2025.102504. Epub 2025 Jan 22.
2
Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension.肝硬化门静脉高压症肝内和肝外血管调节异常的研究进展
Front Med (Lausanne). 2025 Jan 31;12:1515400. doi: 10.3389/fmed.2025.1515400. eCollection 2025.
3
Reply: Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver trial.回复：他汀类药物预防肝硬化并发症：美国对StatLiver试验的效仿。
Hepatol Commun. 2024 Oct 30;8(11). doi: 10.1097/HC9.0000000000000551. eCollection 2024 Nov 1.
本文引用的文献
1
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial.阿托伐他汀治疗肝硬化患者：一项随机、安慰剂对照试验。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000332.
2
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population-based study and validation of risk scores.预测肝硬化患者肝性脑病：一项英国基于人群的研究和风险评分验证。
Hepatol Commun. 2023 Nov 6;7(11). doi: 10.1097/HC9.0000000000000307. eCollection 2023 Nov 1.
3
Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials.他汀类药物和阿司匹林对酒精性肝硬化相关 HCC 风险的影响：全国模拟试验。
Hepatol Commun. 2023 Jan 3;7(1):e0013. doi: 10.1097/HC9.0000000000000013. eCollection 2023 Jan 1.
4
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study.他汀类药物的使用与慢性乙型肝炎肝硬化进展的风险：一项全国性研究，与传统危险因素无关。
Hepatol Commun. 2022 Sep;6(9):2455-2464. doi: 10.1002/hep4.2022. Epub 2022 Jun 29.
5
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.阿托伐他汀可正向调节临床肝细胞癌风险基因特征。
Hepatol Commun. 2022 Sep;6(9):2581-2593. doi: 10.1002/hep4.1991. Epub 2022 Jun 16.
6
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.辛伐他汀和利福昔明治疗可恢复失代偿期肝硬化患者的血浆代谢组学特征。
Hepatol Commun. 2022 May;6(5):1100-1112. doi: 10.1002/hep4.1881. Epub 2021 Dec 28.
7
Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.胆固醇相关性脂肪性肝炎在 NASH 发展中的作用。
Hepatol Commun. 2022 Jan;6(1):12-35. doi: 10.1002/hep4.1801. Epub 2021 Aug 24.
8
Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial.阿托伐他汀预防肝硬化疾病进展和住院治疗的随机、双盲、安慰剂对照试验方案。
BMJ Open. 2020 Jan 23;10(1):e035284. doi: 10.1136/bmjopen-2019-035284.
Zotero 插件